Efficacy and safety of therapeutic vs. prophylactic bemiparin in noncritically ill patients with COVID-19 pneumonia

[1]  J. Douketis,et al.  Anticoagulant therapy for COVID-19: What we have learned and what are the unanswered questions? , 2021, European Journal of Internal Medicine.

[2]  Marcelo A. Falappa,et al.  Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial , 2021, BMJ.

[3]  V. Jiménez‐Yuste,et al.  Therapeutic vs. prophylactic bemiparin in hospitalized patients with non-severe COVID-19 (BEMICOP): an open-label, multicenter, randomized trial , 2021, Thrombosis and Haemostasis.

[4]  J. Halperin,et al.  Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. , 2021, JAMA internal medicine.

[5]  Christopher M. Horvat,et al.  Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 , 2021, The New England journal of medicine.

[6]  Christopher M. Horvat,et al.  Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 , 2021, The New England journal of medicine.

[7]  Á. Avezum,et al.  Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial , 2021, The Lancet.

[8]  G. Lip,et al.  Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19 , 2021, Journal of the American College of Cardiology.

[9]  D. Jiménez,et al.  Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019 , 2020, Chest.

[10]  P. Emery,et al.  Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia , 2020, The Lancet Rheumatology.